Diagnostic & Assessment Strategies for COPD Flashcards

What is the gold standard diagnostic test for COPD?

Answer: Post-bronchodilator spirometry

Spirometry measures lung function, specifically how much air a person can inhale and exhale, and how quickly. Performing this test after administering a bronchodilator helps confirm persistent airflow limitation that is not fully reversible, which is the hallmark of COPD and distinguishes it from conditions like asthma.

Which spirometry result confirms COPD diagnosis?

Answer: FEV1/FVC < 0.70 post-bronchodilator

The FEV1/FVC ratio measures the proportion of air exhaled in the first second (FEV1) relative to the total forced vital capacity (FVC). A ratio of less than 0.70 after bronchodilator administration indicates persistent, irreversible airflow limitation, which is the definitive diagnostic criterion for COPD according to global guidelines.

Which assessment tool is used to evaluate COPD symptom severity and exacerbation risk?

Answer: GOLD ABCD classification

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) ABCD classification system integrates a patient's symptom severity (assessed by mMRC or CAT score) and their history of exacerbations. This comprehensive tool helps clinicians categorize patients and tailor individualized treatment strategies, including pharmacologic and non-pharmacologic interventions, for optimal management.

What is the purpose of a 6-minute walk test (6MWT) in COPD assessment?

Answer: Evaluate functional exercise capacity & oxygen needs

The 6-minute walk test (6MWT) is a practical, submaximal exercise test that assesses a patient's functional exercise capacity and endurance in a real-world setting. It helps evaluate the impact of COPD on daily activities, predict prognosis, and determine the need for supplemental oxygen during exertion, guiding treatment and rehabilitation plans.

Which imaging study is most useful to rule out comorbidities (e.g., lung cancer) in COPD?

Answer: High-resolution CT (HRCT)

While a chest X-ray can show some signs of emphysema, High-resolution CT (HRCT) provides much more detailed images of the lung parenchyma and airways. It is superior for accurately assessing the extent of emphysema and bronchiectasis, and crucially, for detecting or ruling out other significant lung pathologies like lung cancer, which is common in COPD patients.

When should arterial blood gas (ABG) analysis be performed in COPD patients?

Answer: When FEV1 is < 50% predicted or signs of respiratory failure

Arterial blood gas (ABG) analysis provides crucial information about a patient's oxygenation, ventilation, and acid-base status. It is indicated in severe COPD (FEV1 < 50% predicted) or when there are clinical signs of respiratory failure, as it helps identify hypoxemia and hypercapnia, guiding decisions on oxygen therapy and ventilatory support.

What does the mMRC dyspnea scale assess?

Answer: Severity of breathlessness during daily activities

The modified Medical Research Council (mMRC) dyspnea scale is a simple, patient-reported questionnaire that quantifies the impact of breathlessness on a patient's daily activities. It helps categorize symptom severity, which is a key component of the GOLD ABCD assessment for guiding appropriate treatment decisions and monitoring disease progression.

Which lab test is recommended for patients with early-onset COPD or family history?

Answer: Alpha-1 antitrypsin level

Alpha-1 antitrypsin deficiency is a genetic condition that can cause early-onset emphysema, especially in non-smokers or those with a family history of COPD. Screening for AAT levels is crucial in these populations to identify the underlying cause and guide specific management, such as augmentation therapy, which can slow disease progression.

What is the primary goal of COPD staging using the GOLD criteria?

Answer: Tailor pharmacologic & non-pharmacologic therapy

The GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for staging COPD integrate spirometry results, symptom burden (mMRC/CAT), and exacerbation history. This comprehensive assessment allows clinicians to categorize patients into A, B, C, or D groups, which directly guides the selection of appropriate pharmacologic and non-pharmacologic interventions to optimize patient care.